@article {7631,
	title = {Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: Results of a randomized phase III trial},
	journal = {Haematologica},
	volume = {98},
	year = {2013},
	note = {Cited By :27Export Date: 21 February 2017},
	month = {2013},
	pages = {784 - 788},
	abstract = {The MM-015 trial assessed the effect of lenalidomide-based therapy on health-related quality of life. Patients (n=459) with newly diagnosed multiple myeloma aged 65 years or over were randomized 1:1:1 to nine 4-week cycles of lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance; or lenalidomide, melphalan, and prednisone, or melphalan and prednisone, with no maintenance therapy. Patients completed health-related quality of life questionnaires at baseline, after every third treatment cycle, and at treatment end. Health-related quality of life improved in all treatment groups during induction therapy. Patients receiving lenalidomide maintenance had the most pronounced improvements, Global Health Status/Quality of Life (P<0.05), Physical Functioning (P<0.01), and Side Effects of Treatment (P<0.05) out of 6 pre-selected health-related quality of life domains. More patients receiving lenalidomide maintenance achieved minimal important differences (P<0.05 for Physical Functioning). Therefore, lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in patients with newly diagnosed multiple myeloma. (Clinicaltrials.gov identifier NCT00405756). {\textcopyright} 2013 Ferrata Storti Foundation.},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84877072648\&doi=10.3324\%2fhaematol.2012.074534\&partnerID=40\&md5=ee07fe47ff41cb3706a24eb454ed117d},
	author = {Dimopoulos, M.A. and Delforge, M. and H{\'a}jek, R. and Kropff, M. and Petrucci, M.T. and Lewis, P. and Nixon, A. and Zhang, J. and Mei, J. and Palumbo, A.}
}
